ArticleThe Journal of adolescent health : official publication of the Society for Adolescent Medicine2026
Weight Loss Medications in Youth: Decision-Making Experiences, Eating Behaviors, and Uncertainty About Endpoint.
Article in The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults.Obesity pillars · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeTo examine decision-making and experiences with use of weight loss medications by adolescents and young adults (AYAs) with obesity.
methodsParticipants included AYA 12-22 years old with obesity who were considering starting (PRE) or were using weight loss medications (POST), including semaglutide, liraglutide, tirzepatide, or phentermine ± topiramate. Caregivers of AYA participants were also invited to participate. Semistructured interviews were audio recorded on a video conferencing platform by trained research team members. A rapid qualitative analysis approach was used to summarize themes.
resultsA total of 29 AYA (9 PRE, 20 POST; 55% female; mean age 16.7 ± 2.5 years) and 23 caregivers (7 PRE, 16 POST; 22 mothers, 1 grandmother) participated. Themes included: decision-making: family, peers, doctors, media, finances, and risk-benefit considerations were influential, with AYAs emphasizing weight loss and caregivers emphasizing health; appetite and eating behaviors: high appetite was a key reason for use, "binges" were reported by PRE AYA and POST AYA pretreatment, and medications reduced appetite and food noise; physical, mental, and social experience: improved AYA well-being was reported, yet stigma about medication usage was a concern; parental role: parents provided key practical and emotional support for use; and thinking about future use: AYA and caregivers expressed positive experiences overall and uncertainty over discontinuation decisions. DISCUSSION: A shared decision-making approach leveraging caregiver support for initiation, ongoing use, and discontinuation is needed for AYA considering weight loss medications. Future research should investigate strategies to assess for disordered eating in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.